ClinicalTrials.gg
RecruitingNCT06253611BIGUpdated Sep 22, 2025

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

A Phase 2 interventional study of Nivolumab and FOLFOX regimen in Gastric Cancer, sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group. Recruiting at 37 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 159 studies in Stomach Neoplasms with a site in France — 39 open to participants now, 58 under way, 12 of them phase 3. Stomach Neoplasms · France.

Planned enrollment
92nd of 140
120 · median 183
Started
2024
with 8 others
Phase 2
40 of 159
8 open now
Primary completion
2027-09
later than 27 of 57 live
Registered
137th of 159
by date
Lead sponsor
5 of 159
GERCOR - Multidisciplinary Oncology Cooperative Group

Among the 159 studies in Stomach Neoplasms with a site in France, this one is the 92nd largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2024, is one of 40 in phase 2, reaches primary completion later than 27 of the 57 other live ones, and was the 137th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

39 of the 159 studies in Stomach Neoplasms with a site in France are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies in Stomach Neoplasms with a site in France, or all of them as a file.
02

Study summary

This is a randomized non-comparative, multicenter phase II study in patients with PD-L1 PD-L1 combined positive score (CPS) ≥5 advanced gastric cancer to evaluate the efficacy and safety of nivolumab and FOLFOX in combination with EXL01 as first-line treatment.

After signing the informed consent form, and upon confirmation of the patient's eligibility, patients will be randomized in a 2:1 ratio to either the nivolumab and FOLFOX plus EXL01 arm (experimental) or the nivolumab and FOLFOX arm (control). In both arms, treatment will be given until PD, unacceptable toxicity or for a maximum of 24 months (52 cycles).

Read the detailed description

The primary objective of the study is to assess the objective response rate (ORR) at 4 months (based on Response Evaluation Criteria in Solid Tumor [RECIST] criteria v1.1) of patients with PD-L1 CPS ≥ 5 advanced gastric cancer treated by EXL01 plus nivolumab and FOLFOX as first-line treatment.

With a randomization ratio of 2:1 it will be necessary to randomize 40 patients in the control arm, 80 patients in the experimental arm and so a total of 120 evaluable patients in the study. Randomization will be stratified by PD-L1 expression level, center, and prior gastrectomy.

In the experimental arm, the primary analysis will be on modified intent-to-treat (mITT) population. Confirmative analysis will be conducted firstly in the ITT population and secondly, in the Per Protocol (PP). Analyses of safety will be conducted in safety population.

The Kaplan-Meier method will be used to estimate time to event endpoints and described using the median and event-free rates over time with CI.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Patients must have dated and signed an approved written form. This must be obtained before the performance of any protocol-related procedures that are not part of normal patient care.
  2. Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study,

    Target Population

  3. Inoperable, advanced, or gastric cancer or gastroesophageal junction or distal esophageal carcinoma and confirmed predominant adenocarcinoma,
  4. Expression of with a combined positive score (PD-L1 CPS) ≥5, Note: information must be available at the time of inclusion, the examination will be performed locally in the center and secondarily confirmed centrally,
  5. No prior systemic cancer treatment given as primary therapy for advanced nonresectable or metastatic disease, Note: if patient received /adjuvant therapy, this therapy should be completed at least 6 months prior to the diagnosis of metastatic or recurrent disease is made. Palliative radiotherapy is allowed and must be completed 2 weeks prior to randomization,
  6. At least one as assessed by computed tomography (CT)-scan or magnetic resonance imaging (MRI) according to (RECIST) v 1.1 and feasibility of repeated radiological assessments; radiographic tumor assessment should be performed within 28 days prior to randomization,
  7. performance status (ECOG PS) of 0 or 1,
  8. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to randomization of study treatment:

    1. White blood cell ≥ 2000/μL;
    2. Neutrophils ≥ 2000/μL;
    3. ≥ 100.000/μL;
    4. ≥ 9.0 g/dL;
    5. Serum albumin ≥ 30 g/L;
    6. Serum creatinine level ≤ 150 μM and calculated (Cockcroft-Gault) > 50 mL/minute,
    7. Total ≤ 1.5 x upper normal limit ();
    8. (ALT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN if liver metastases are present);
    9. Aspartame aminotransferase (AST) ≤ 3.0 x ULN (or ≤ 5.0 x ULN if liver metastases are present);
    10. Potassium ≥ 1.0 x lower limit of normal (LLN),
    11. Magnesium ≥ 1.0 x LLN,
    12. Calcium ≥ 1.0 x LLN,
  9. Baseline- interval ≤ 450 msec for males and ≤ 470 msec for females,
  10. Availability of a representative tumor tissue specimen for exploratory translational research; tumor tissue samples, either formalin- fixed paraffin-embedded (FFPE) tissue block or unstained tumor tissue sections (minimum of 20 positively charged slides) from primary or metastatic site must be submitted to the central laboratory,
  11. Registration in a national health care system (PUMa-Protection Universelle Maladie included.

    Age and reproductive status

  12. Age ≥ 18 years,
  13. Women must not be pregnant, breastfeeding, or expecting to conceive during the study,
  14. Reproductive status:

    1. Women of (WOCBP) must have a negative serum pregnancy test within 72 hours prior to the start of study drug,
    2. WOCBP must agree to use an adequate method of or birth control for the duration of study treatment and 5 months (nivolumab), 9 months (oxaliplatin), 6 months (5-FU) or at least 1 month (EXL01) of the patient's last dose of the study drug,
    3. Males who are fertile and sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment and 6 months (nivolumab, oxaliplatin, or 5-FU) or at least 1 month (EXL01) after the last dose of study treatment. In addition, males must be willing to refrain from sperm donation during this time,

Exclusion Criteria:

Target Disease Exceptions

  1. Known positive status or unknown HER-2 status before inclusion,
  2. Active or known history of ,
  3. Ascites, which cannot be controlled with appropriate interventions,

    Exclusion criteria related to medical history and concurrent disease

  4. Prior active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast,
  5. Active, known, or suspected disease; type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted,
  6. Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity,
  7. Prior treatment with an anti-PD(L)1, anti-LAG-3, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co- stimulation or immune checkpoint pathways, including prior therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents,
  8. Condition requiring systemic treatment with either (>10 mg daily prednisone equivalent) or other medications within 14 days (2 weeks) of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted prior to randomization in the absence of active autoimmune disease,
  9. Persistence of toxicity (The National Cancer Institute Common Terminology Criteria for Adverse Event [] v 5.0) grade >1 related to prior anticancer treatments,
  10. Major surgery within 28 days (4 weeks) prior to first dose of study treatment, Note: Participants who had surgery >4 weeks prior to screening must have recovered adequately from any toxicity and/or complications from the surgery or trauma prior to starting study intervention.
  11. Concomitant unplanned antitumor therapy (e.g., chemotherapy, molecular targeted therapy, radiotherapy, immunotherapy),

    Exclusion criteria related to EXL01

  12. GI obstruction, poor oral intake, or difficulty in taking oral medication or difficulties in swallowing; nasogastric tubes are not permitted,
  13. Known GI malabsorption,
  14. Is currently participating in or has participated in a study with an compound within 28 days prior to the first dose of study treatment, Note: Participants who have entered the follow-up phase of an investigational study may participate so long as it has been at least 3 months since the last dose of the previous investigational agent,
  15. Prior bone marrow transplantation or prior solid organ transplantation,
  16. Fecal microbiota transplant within 3 months prior to screening, Note: Patients must have recovered adequately from the toxicity and/or complications from the treatment prior to starting study intervention.
  17. Current probiotics administration, or planned probiotics administration during treatment course is not allowed, Note: The following therapies should be avoided during the study; however, they are not prohibited if, in the assessment of the

    Investigator, they are required for clinical management:

    • Nonsteroidal anti-inflammatories,
    • Antacids,
    • Proton-pump inhibitors.
  18. Excessive alcohol intake: moderate consumption, defined as no more than 1 drink per day for women and no more than 2 drinks per day for men, is permitted,
  19. Known allergy and/or to any component or of study treatments (nivolumab, EXL01), any other live pro- biotherapeutic product, and/or to soybean or soy-containing products,
  20. Known history or newly diagnosed GI parasitic infection within 3 months prior to screening, Note: Patients must have recovered adequately from the toxicity and/or complications from the treatment prior to starting study intervention,
  21. Active inflammatory intestinal disease (Crohn disease, Hemorrhagic recto-colitis, coeliac disease) or any serious chronic intestinal disease with uncontrolled diarrhea, or other inflammatory disease requiring anti-inflammatory medications (according to exclusion criteria n°8),

    Exclusion criteria related to chemotherapy

  22. Active or chronic virus (HBV), virus (HCV) and/or infection (HIV 1/2 antibodies).

    Participants are eligible if they:

    • Have controlled HCV load defined as undetectable hepatitis C RNA by polymerase chain reaction either spontaneously or in response to a successful prior course of anti-hepatitis C therapy,
    • Have received HBV vaccination with only anti-HBs positivity and no clinical signs of hepatitis,
    • Are HBV surface antigen (HBsAg)- and anti- Hepatitis B core antibody (HBc)+ (i.e., those who have cleared HBV after infection),
    • Are HBsAg+ with chronic HBV infection (lasting 6 months or longer) and meet conditions below:

      • HBV DNA viral load \<100 IU/mL,
      • Have normal transaminase values, or, if liver metastases are present, abnormal transaminases, with a result of AST/ALT \<3 × ULN, which are not attributable to HBV infection,
      • Start or maintain antiviral treatment if clinically indicated as per the investigator,
  23. Any (attenuated) use within 28 days (4 weeks) prior to randomization, while in the study; live vaccines include, but are not limited to, the following: yellow fever, varicella, shingles, measles, mumps, rubella, tuberculosis, rotavirus, influenza,
  24. Ongoing or concomitant use of the antiviral drug sorivudine or its chemically related analogs, such as brivudine,
  25. Dihydropyrimidine dehydrogenase deficiency (DPD; uracilemia dosage >16 ng/ml), Uracilemia dosing results must be available before inclusion,
  26. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of the patient's safety or study results,
  27. Known peripheral sensory neuropathy with functional impairment according exclusion criteria n°9) prior to first treatment, according to the Summary of product characteristics (SmPC) of oxaliplatin,
  28. Known potentially serious infection, according to the SmPC of 5-FU
  29. Has active heart disease or myocardial infarction within 6 months given the cardiotoxicity of 5-FU, according to the SmPC of 5-FU,
  30. Known history of hypersensitivity to 5-FU, oxaliplatin, or leucovorin, or to any of their excipients, according to the SmPCs of these products.

    Exclusion criteria related to geographical, social, and legal issues

  31. Impossibility of submitting to the medical follow-up of the study for geographical, social, or psychiatric illness,
  32. Patient under a legal protection regime (guardianship, curatorship, judicial safeguard) or administrative decision or incapable of giving his/her consent.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Nivolumab Combined With FOLFOX and EXL01

    Nivolumab 240 mg IV q2w and FOLFOX q2w plus EXL01 orally once daily

    Drug: Nivolumab · Drug: FOLFOX regimen · Biological: EXL01

  • Active comparator
    Nivolumab and FOLFOX

    Nivolumab 240 mg IV q2w and FOLFOX q2w

    Drug: Nivolumab · Drug: FOLFOX regimen

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) at 4 months

    ORR measured at 4 months post randomization in patients with PD-L1 CPS ≥5 advanced gastric cancer treated by first-line EXL01 plus nivolumab and FOLFOX. ORR at 4 months is defined as the number of patients with a CR or PR evaluated by RECIST v 1.1 criteria divided by the number of patients evaluable.

    Time frame: At 4 months

Secondary outcomes

  1. Overall survival (OS)

    OS with nivolumab plus FOLFOX with or without EXL01. OS is defined as the time between the date of randomization and the date of death from any cause.

    Time frame: Maximum 3 years after randomization

  2. Progression-free survival (PFS)

    PFS per RECIST v 1.1 and iRECIST of nivolumab plus FOLFOX with or without EXL01. PFS is defined as the time from randomization to the date of the first documented PD determined by the Investigator assessment by RECIST 1.1 or death due to any cause, whichever occurs first.

    Time frame: Maximum 3 years after randomization

  3. Assessment of safety profile

    Safety of nivolumab plus FOLFOX with or without EXL01. Safety will be measured by the incidence of Adverse Events (AEs), Serious AEs (SAEs), deaths, laboratory abnormalities, and specific immune-related AEs (hepatitis, colitis, myositis, endocrinopathies).

    Time frame: Maximum 3 years after randomization

  4. Duration of response (DoR)

    DoR with FOLFOX plus nivolumab with or without EXL01. DoR is defined as the time between the date of first documented response (complete response \[CR\] or partial response \[PR\]) to the date of the first disease progression, per RECIST 1.1 or death due to any cause, whichever occurs first. For patients who neither progress nor die, the duration of objective response will be censored at the same time they were censored for the primary definition of PFS.

    Time frame: Maximum 3 years after randomization

  5. Objective response rate (ORR)

    ORR per RECIST v 1.1 criteria nivolumab plus FOLFOX with or without EXL01. ORR is defined as the number of patients with the best overall response (BOR) of CR or PR divided by the number of measurable patients with target lesion at baseline. BOR is defined as the best response designation, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1) or the date of subsequent anti-cancer therapy, whichever occurs first.

    Time frame: Maximum 3 years after randomization

  6. 2-year and 3-year OS

    2-year and 3-year OS rate of nivolumab plus FOLFOX with or without EXL01

    Time frame: At 2 years and 3 years

  7. 1-year and 2-year PFS

    1-year and 2-year PFS rates per RECIST v 1.1 and iRECIST (immune RECIST) criteria with nivolumab plus FOLFOX with or without EXL01

    Time frame: At 1 year and at 2 years

07

Study locations

11 of 37 sites recruiting
  • Institut de Cancerologie de L'Ouest Paul Papin
    Angers, France
    Not yet recruiting
    • Sandrine HIRET, MD · Contact
  • Clinique Sainte Catherine
    Avignon, France
    Recruiting
    • Clemence TOULLEC, MD · Contact
  • Centre Hospitalier Universitaire Jean Minjoz
    Besançon, France
    Recruiting
    • Angelique VIENOT, MD · Contact
  • Institut Bergonie
    Bordeaux, France
    Not yet recruiting
    • Simon PERNOT, MD · Contact
  • Centre Hospitalier Universitaire Morvan
    Brest, France
    Not yet recruiting
    • Estelle Dhamelincourt, MD · Contact
  • Centre Francois Baclesse
    Caen, France
    Not yet recruiting
    • Aurélie PARZY, MD · Contact
  • Centre Hospitalier de Cholet
    Cholet, France
    Recruiting
    • Thonas CENTRE HOSPITALIER DE CHOLET, MD · Contact
  • Centre Hospitalier Universitaire Clermont Ferrand - Site Estaing
    Clermont-Ferrand, France
    Not yet recruiting
    • Marine JARY, MD · Contact
  • Centre Hospitalier Henri Mondor
    Créteil, France
    Not yet recruiting
    • Charlotte Fenioux, MD · Contact
  • Centre Georges Francois Leclerc
    Dijon, France
    Recruiting
    • Francois GHIRINGHELLI, MD · Contact
  • Centre Hospitalier Universitaire Grenoble Alpes - Site Nord - Hopital Michallon
    La Tronche, France
    Not yet recruiting
    • Gaël ROTH, MD · Contact
  • Centre Hospitalier Universitaire de Lille
    Lille, France
    Recruiting
    • Anthony TURPIN, MD · Contact
  • Hopital Leon Berard
    Lyon, France
    Recruiting
    • Clelia COUTZAC, MD · Contact
  • Hopital Prive Jean Mermoz
    Lyon, France
    Not yet recruiting
    • Pascal ARTRU, MD · Contact
  • Hopital La Timone
    Marseille, France
    Not yet recruiting
    • Laëtitia DAHAN, MD · Contact
  • Centre Hospitalier Universitaire de Montpellier
    Montpellier, France
    Not yet recruiting
    • Eric ASSENAT, MD · Contact
  • Centre Hospitalier Universitaire Nantes - Hopital Hotel Dieu
    Nantes, France
    Not yet recruiting
    • Tamara MATYSIAK-BUDNIK, MD · Contact
  • Centre Antoine Lacassagne
    Nice, France
    Recruiting
    • Ludovic Evesque, MD · Contact
  • Centre Hospitalier Cochin
    Paris, France
    Not yet recruiting
    • Anna PELLAT, MD · Contact
  • Groupe Hospitalier Diaconesses Croix Saint-Simon
    Paris, France
    Not yet recruiting
    • Olivier DUBREUIL, MD · Contact
  • Hopital Europeen Georges Pompidou
    Paris, France
    Not yet recruiting
    • Aziz Zaanan, MD · Contact
  • Hopital Saint Antoine
    Paris, France
    Recruiting
    • Romain COHEN, MD · Contact
  • Hopital Saint-Louis
    Paris, France
    Not yet recruiting
    • Thomas APARICIO, MD · Contact
  • Institut Curie
    Paris, France
    Not yet recruiting
    • Cindy NEUZILLET, MD · Contact
  • Institut Gustave Roussy
    Paris, France
    Not yet recruiting
    • Cristina SMOLENSCHI, MD · Contact
  • Institut Mutualiste Montsouris
    Paris, France
    Not yet recruiting
    • Emilie SOULARUE, MD · Contact
  • Centre Hospitalier Universitaire de Poitiers - Hopital de La Miletrie
    Poitiers, France
    Recruiting
    • David TOUGERON, MD · Contact
  • Centre Hospitalier Universitaire Reims Hopital Robert Debre
    Reims, France
    Recruiting
    • Olivier BOUCHE, MD · Contact
  • Institut Jean Godinot
    Reims, France
    Not yet recruiting
    • Damien BOTSEN, MD · Contact
  • Centre Hospitalier Universitaire de Rennes
    Rennes, France
    Not yet recruiting
    • Astrid LIEVRE, MD · Contact
  • Hopital D'Instruction Des Armées Bégin
    Saint-Mandé, France
    Not yet recruiting
    • Julie LAVOLE, MD · Contact
  • Centre Hospitalier Saint-Malo
    St-Malo, France
    Not yet recruiting
    • Romain DESGRIPPES, MD · Contact
  • Institut de Cancerologie Strasbourg Europe
    Strasbourg, France
    Not yet recruiting
    • Meher BEN ABDELGHANI, MD · Contact
  • Centre Hospitalier Universitaire Tours - Hopital Trousseau
    Tours, France
    Not yet recruiting
    • Elise DOUARD TOURNET, MD · Contact
  • CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE NANCY Site Brabois
    Vandœuvre-lès-Nancy, France
    Not yet recruiting
    • Marie MULLER, MD · Contact
  • Hopital Paul Brousse
    Villejuif, France
    Recruiting
    • Pascal Hammel, MD · Contact
  • Medipole Hopital Mutualiste Lyon-Villeurbanne
    Villeurbanne, France
    Not yet recruiting
    • Mathieu SARABI, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 41 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 12, 2024
StartActual
Apr 16, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Apr 2029
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06253611
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
Apr 16, 2024
Primary completion
Sep 2027 (estimated)
Completion
Apr 2029 (estimated)
Last update
Sep 22, 2025

Study contacts

Marie-Line GARCIA LARNICOL, MD
Contact
marie-line.garcia-larnicol@gercor.com.fr
+33 (01) 40 29 85 04
Romain Cohen, MD
principal investigator · Saint-Antoine Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01

Start the discussion